Improved Speed to Clinic by Increasing Automation in Cell Line Development
14th November 2017
Category: Cell Line Development
By: Dr Christoph Zehe - Lead Scientist, Dr Monika Holeiter - Senior Scientist, Technology Development,
“Speed to Clinic” is a crucial measure for successful drug development. As a leading provider of stable cell lines, Sartorius Stedim Cellca strives to contribute to this goal by increasing the degree of automation in its Cell Line Development (CLD) technology. While maintaining consistently high quality of the recombinant products, we develop an automation strategy for our CLD platform. Minimizing the manual workload will increase productivity and facilitate reproducibility.
Semi-automated Systems: Islands of Automation
Our CLD platform perfectly aligns the CHO DG44 host cell line, expression vector, media system and upstream process design for highly efficient expression of easy- and difficult-to-express proteins. Currently, we have already introduced a couple of fully- or semi-automated instruments (Cellavista – Synentec, Vi-Cell – Beckman, ambr15 – Sartorius). Robotic microtiter plate handlers will further reduce the need for manual handling at different process stages (see Figure 1).
Figure 1: Islands of automation: A higher degree of automation can be achieved by using flexible robotic microtiter plate handlers (e.g. S-Lab, PAA) capable of adapting to a variety of specialized semi-automated instruments (iQue Screener PLUS, Multidrop combi, Cellavista).
An even higher degree of automation for CLD will be realized in a fully enclosed class 2 type workstation (PAA), reducing manual handling to a minimum. The system will contain instruments on removable carts which are still available for manual usage and will be able to handle all common multiwell formats. Thereby, a maximum return on the investment and highest flexibility for latest developments is ensured. As a result, work package delivery will be possible in an improved high throughput manner and human errors will be reduced.